Methylphenidate

BNF:

4.4

Status:

Amber

Decision Date:

None

Comments

See shared care guidelines for drugs used in the management of ADHD

First line drug choice

MHRA drug safety update - methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations. (Sep 2022)

Amber Drug Classifications

• 1: Requiring specialist assessment to enable patient selection and initiation of treatment
• 3: Requiring short or medium term specialist monitoring of toxicity

search again